Medical oncologist Guenther Koehne explains how remission was achieved using WT1-specific T-cell therapy in a patient with refractory multiple myeloma and plasma cell leukemia.
Medical oncologist Alexander Lesokhin discusses a phase I dose escalation of an anti-PD-1 immunotherapy in patients with hematologic cancers.
Medical Director of the Cytotherapy Laboratory Guenther Koehne discusses WT1-specific cellular immune responses in patients with relapsed multiple myeloma and high-risk cytogenetics.
Our multidisciplinary team approach to multiple myeloma and related diseases draws on the expertise of hematologic oncologists, radiation oncologists, radiologists, pathologists, and bone marrow transplant and pain specialists, among others, who collaborate closely on each patient’s care. We have decades of experience in treating these conditions, and were among the first to recognize the therapeutic value of drugs such as thalidomide and proteasome inhibitors, as well as the predictive power of a serum-free light chain assay for assessing relapse risk. We continue our successful program in stem cell transplantation as we simultaneously test new treatments, diagnostic tools, and DNA testing approaches for projecting individual cancer response.